Biopharmaceuticals

BioLife Solutions Announces Changes to Board of Directors

Retrieved on: 
Wednesday, July 14, 2021
Biopharmaceuticals, Bioproduction

BOTHELL, Wash., July 14, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS)("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced changes to its board of directors.

Key Points: 
  • BOTHELL, Wash., July 14, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS)("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced changes to its board of directors.
  • His experience, mentorship and board leadership have been instrumental in helping craft our strategy and drive our growth at BioLife."
  • Current Chief Executive Officer and director, Mike Rice, has been appointed by the board of directors as the new chairman.
  • BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services.

Agenus Acquires 120 Acres in the Heart of the California Biomanufacturing Center in Vacaville

Retrieved on: 
Friday, July 9, 2021
Life sciences, Articles, Economic taxonomy, Biopharmaceuticals, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry, Vacaville, California

In terms of high-quality jobs and commitment to the region, this is an enormous win for Vacaville.

Key Points: 
  • In terms of high-quality jobs and commitment to the region, this is an enormous win for Vacaville.
  • In October of 2020, the City of Vacaville announced the start of the next generation of its world class biomanufacturing cluster dubbed the California Biomanufacturing Center with the identification of 300 acres available for development.
  • The Agenus site is in the heart of the California Biomanufacturing Center at the intersection of Interstates 80 and 505.
  • CBC works with stakeholders to address biomanufacturing challenges and ensure that Vacaville remains a place for the industry to flourish.

Jacobson Pharma Announces FY2021 Annual Results

Retrieved on: 
Tuesday, June 29, 2021
Life sciences, Biotechnology, Articles, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Pharma

HONG KONG, June 29, 2021 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2021 (the "FY2021" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2021 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2021 (the "FY2021" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated with the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2021 ACN Newswire .

AMS 2020 Specialty Drug Trends Report Highlights Egregious Overspend

Retrieved on: 
Tuesday, June 22, 2021
Life sciences, Articles, Biotechnology, Business intelligence, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Predictive analytics

LYNNFIELD, Mass., June 22, 2021 /PRNewswire/ --AMS, a healthcare IT company that provides clinical insights and financial analysis of the costliest and most complex medical claims, released their 2020 Specialty Drug Trends Report today, highlighting the need for predictive analytics to combat pervasive drug overspend.

Key Points: 
  • LYNNFIELD, Mass., June 22, 2021 /PRNewswire/ --AMS, a healthcare IT company that provides clinical insights and financial analysis of the costliest and most complex medical claims, released their 2020 Specialty Drug Trends Report today, highlighting the need for predictive analytics to combat pervasive drug overspend.
  • AMS research reveals that payers are not being judicious with their specialty drug expenditures because they have little insight into the actual drivers of high-cost claims and members.
  • Fewer than 2% of the U.S. population utilized specialty drugs
    Notable for this year's report, specialty drug costs and trends sections were greatly expanded, allowing for greater depth & breadth of data.
  • "As one can see from the report, specialty drug prices are high enough already.

RxLightning Announces Addition of New Board Members Following $3 Million Seed Round Led by HealthX Ventures

Retrieved on: 
Wednesday, June 16, 2021
Life sciences, Biotechnology, Articles, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Business process management

To view the full announcement, including downloadable images, bios, and more, click here .

Key Points: 
  • To view the full announcement, including downloadable images, bios, and more, click here .
  • Healthcare heavyweights Brad Fluegel and Taha Jangda join RxLightning Board.
  • RxLightning's digital solution to the cumbersome, manual process of specialty drug enrollment gaining rapid market interest and adoption.
  • Founded in New Albany, Indiana in 2020, RxLightning digitizes, automates and streamlines the historically complicated manual enrollment process of starting a patient on specialty medications.

BioLife Solutions Adopts New Brand Identity

Retrieved on: 
Tuesday, June 15, 2021
Biopharmaceuticals, Bioproduction

BOTHELL, Wash., June 15, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS)("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced the launch of its new corporate brand identity, redesigned logo, and website.

Key Points: 
  • BOTHELL, Wash., June 15, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS)("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced the launch of its new corporate brand identity, redesigned logo, and website.
  • The new brand identity was created to better reflect BioLife's expanded portfolio of bioproduction tools and services.
  • The new BioLife corporate website launched this week with this new visual identity and includes the full website integration of several companies previously acquired by BioLife.
  • BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services.

Kansas Manufacturing Solutions and BioKansas Partner to Help Kansas Biomanufacturers Prosper

Retrieved on: 
Thursday, June 3, 2021
Research, General Health, Training, Other Education, University, Other Manufacturing, Education, Science, Biotechnology, Manufacturing, Other Science, Health, Life sciences, Regions of the United States, Articles, Pharmaceutical industry, Biomanufacturing, Biopharmaceuticals, Biotechnology, Food industry, KANSAS, Manufacturing, National Institute of Standards and Technology

Kansas Manufacturing Solutions (KMS), a trusted advisor to Kansas manufacturers, and BioKansas, a non-profit organization dedicated to supporting and growing Kansas bioscience ecosystem, are pleased to announce their new partnership to increase the prosperity of Kansas companies engaged in biomanufacturing.

Key Points: 
  • Kansas Manufacturing Solutions (KMS), a trusted advisor to Kansas manufacturers, and BioKansas, a non-profit organization dedicated to supporting and growing Kansas bioscience ecosystem, are pleased to announce their new partnership to increase the prosperity of Kansas companies engaged in biomanufacturing.
  • Through this extended partnership, KMS and BioKansas aim to ensure that Kansas biomanufacturers are well positioned to increase productivity and integrate advanced manufacturing technologies to compete in the growing bioscience marketplace.
  • Kansas Manufacturing Solutions is a Kansas statewide manufacturing assistance center partially funded by the NIST Manufacturing Extension Partnership (MEP).
  • Kansas Manufacturing Solutions grows Kansas manufacturing by delivering solutions to small and medium sized manufacturers and is the only advisor focused on this industry in Kansas with value driven results.

Avantor® Acquires RIM Bio; Expands Bioproduction Footprint into China

Retrieved on: 
Tuesday, June 1, 2021
Biopharmaceuticals, Bioproduction, Avantor, BlackBerry Limited, Cleanroom software engineering, Companies, Financial markets

Avantor will leverage RIM Bio's proprietary technologies and best-in-class lead times to provide single-use customers with a differentiated offering.

Key Points: 
  • Avantor will leverage RIM Bio's proprietary technologies and best-in-class lead times to provide single-use customers with a differentiated offering.
  • Dr. Ger Brophy, Executive Vice President, Biopharma Production at Avantor, said, "Adding RIM Bio enables Avantor to better serve our customers by expanding our single-use manufacturing , distribution, and cleanroom capabilities to the AMEA region.
  • RIM serves as an anchor for us to build our presence in this key region, as we better position Avantor to capture long-term opportunities in the growing, global Bioproduction space."
  • In addition, all forward-looking statements speak only as of the date of this press release.

WhiteLab Genomics and the Accelerator for Technological Research in Genomic Therapies Announce Their Collaboration on Artificial Intelligence for the Bioproduction of Gene Therapies

Retrieved on: 
Monday, May 31, 2021
Other Health, Software, Research, Data management, Technology, Genetics, Clinical trials, Science, Biotechnology, Other Technology, Other Science, Health, Biopharmaceuticals, Bioproduction, ART-TG, WhiteLab Genomics, ART-TG, WHITELAB GENOMICS

The pharmaceutical manufacture of these Advanced Medicinal Therapies requires acceleration in terms of standardization and process control to respond to their growth.

Key Points: 
  • The pharmaceutical manufacture of these Advanced Medicinal Therapies requires acceleration in terms of standardization and process control to respond to their growth.
  • "The collaboration with ART-TG allows us to work with global experts in the field of lentiviral vector bioproduction," said David Del Bourgo, CEO and co-founder of WhiteLab Genomics.
  • Created in 2019 by David Del Bourgo, Julien Cottineau and Lucia Cinque, WhiteLab Genomics is a French start-up specializing in artificial intelligence solutions dedicated to biotherapies such as gene and cell therapies.
  • WhiteLab Genomics makes this unique technology available to its customers via the Catalyst platform available in SaaS mode.

Veradigm Announces Collaboration With Lash Group to Streamline Patient Care

Retrieved on: 
Tuesday, May 25, 2021
Health, Data management, Pharmaceutical, Technology, Software, Life sciences, Biotechnology, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Allscripts, Electronic health record, Lash, Streamlines, streaklines, and pathlines, Business process management, Articles, Veradigm®, Allscripts, VERADIGM®, ALLSCRIPTS

This relationship will enable specialty medications, supported by Lash Group, to be available for management within the Veradigm AccelRx platform, which streamlines the specialty enrollment process for users of Veradigm, Allscripts and other electronic health record (EHR) software vendors.

Key Points: 
  • This relationship will enable specialty medications, supported by Lash Group, to be available for management within the Veradigm AccelRx platform, which streamlines the specialty enrollment process for users of Veradigm, Allscripts and other electronic health record (EHR) software vendors.
  • Through this collaboration, Veradigm and Lash Group can deliver a frictionless solution that will drive efficiency, resulting in a streamlined process and increased speed-to-therapy.
  • This strategic relationship with Lash Group is a major step in Veradigms progress toward expediting the specialty drug review, approval and fulfillment process, says Tom Langan, Veradigm CEO.
  • In collaborating with a market leader with extensive reach like Lash Group, we enable our broad network of providers to access even more specialty medications through Veradigm AccelRx.